F M Investments LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

F M Investments LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,404 shares of the biotechnology company's stock, valued at approximately $848,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of UTHR. Quantinno Capital Management LP increased its stake in shares of United Therapeutics by 32.7% in the third quarter. Quantinno Capital Management LP now owns 1,308 shares of the biotechnology company's stock worth $469,000 after buying an additional 322 shares during the last quarter. Orion Portfolio Solutions LLC increased its position in shares of United Therapeutics by 60.1% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 3,286 shares of the biotechnology company's stock worth $1,178,000 after purchasing an additional 1,233 shares during the last quarter. MML Investors Services LLC bought a new position in shares of United Therapeutics during the third quarter worth about $245,000. Geode Capital Management LLC grew its stake in United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock worth $391,459,000 after purchasing an additional 45,566 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its holdings in United Therapeutics by 3.8% in the third quarter. Coldstream Capital Management Inc. now owns 2,166 shares of the biotechnology company's stock valued at $779,000 after buying an additional 79 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $388.25.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $955,319.67. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 80,500 shares of company stock valued at $27,849,960. Company insiders own 11.90% of the company's stock.

United Therapeutics Stock Down 0.1 %

United Therapeutics stock traded down $0.37 during mid-day trading on Thursday, hitting $284.82. 82,672 shares of the company's stock traded hands, compared to its average volume of 451,911. United Therapeutics Co. has a one year low of $232.84 and a one year high of $417.82. The company has a market cap of $12.79 billion, a PE ratio of 12.46, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The firm has a 50 day moving average price of $319.20 and a 200 day moving average price of $349.67.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the previous year, the business earned $4.36 earnings per share. On average, analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.